<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3230">
  <stage>Registered</stage>
  <submitdate>11/07/2011</submitdate>
  <approvaldate>11/07/2011</approvaldate>
  <nctid>NCT01392495</nctid>
  <trial_identification>
    <studytitle>Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)</studytitle>
    <scientifictitle>An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-021960-14</secondaryid>
    <secondaryid>CQTI571A2102E1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Arterial Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Imatinib

Experimental: QTI571 - Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).


Treatment: drugs: Imatinib
200 mg or 400 mg qd

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Patients With Adverse Events, Serious Adverse Events and Deaths - Adverse event monitoring was conducted throughout the trial.</outcome>
      <timepoint>144 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in the Six Minute Walk Distance (6MWD)</outcome>
      <timepoint>baseline, 144 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Clinical Worsening (TTCW) Endpoints</outcome>
      <timepoint>144 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Medical Resource Utilization</outcome>
      <timepoint>144 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients who completed in CQTI571A2102 clinical trial including all Study Completion
             assessments at the end of study visit met the eligibility criteria for that study and
             did not meet withdrawal criteria for safety reasons during study conduct</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with left ventricular ejection fraction (LVEF) &lt; 45%

          -  Patients with thrombocytopenia, platelet count &lt; 50 x109/L (50 x 103/ÂµL).

          -  Patients with uncontrolled systemic arterial hypertension, systolic pressure &gt; 160
             mmHg or diastolic pressure &gt; 90 mmHg.

          -  Patients with a QTcF &gt; 450 ms for males and &gt; 470 ms for females in the absence of
             right bundle branch block.

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>17</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Novartis Investigative Site - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Vilnius</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study was an extension to study CQTI571A2102 and was to evaluate the long-term safety,
      tolerability and efficacy of QTI571 (imatinib) in severe pulmonary arterial hypertension
      patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01392495</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>